To date, the primary focus of analyses of FcRn expression in tumors has been directed towards investigating the role that infiltrating, FcRn-positive hematopoietic cells play in increasing cross-presentation of tumor antigens in the form of immune complexes to CD8+ T cells [25]. The gene discussed is FCGRT; the disease is neoplasm.